{"id":"https://openalex.org/W4361957952","doi":"https://doi.org/10.1158/1535-7163.c.6532041.v1","title":"Data from Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia","display_name":"Data from Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361957952","doi":"https://doi.org/10.1158/1535-7163.c.6532041.v1"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.c.6532041.v1","doi":"https://doi.org/10.1158/1535-7163.c.6532041.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.c.6532041.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1535-7163.c.6532041.v1","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5077955893","display_name":"Shuiying Hu","orcid":"https://orcid.org/0000-0002-9806-7734","observed_orcids":["https://orcid.org/0000-0002-9806-7734"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shuiying Hu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102768881","display_name":"Hongmei Niu","orcid":"https://orcid.org/0000-0001-8660-2544","observed_orcids":["https://orcid.org/0000-0001-8660-2544"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hongmei Niu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017243467","display_name":"Patton Minkin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Patton Minkin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034265050","display_name":"Shelley J. Orwick","orcid":"https://orcid.org/0000-0002-4537-1409","observed_orcids":["https://orcid.org/0000-0002-4537-1409"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shelley Orwick","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036019071","display_name":"Akira Shimada","orcid":"https://orcid.org/0000-0001-5207-3779","observed_orcids":["https://orcid.org/0000-0001-5207-3779"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Akira Shimada","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075936752","display_name":"Hiroto Inaba","orcid":"https://orcid.org/0000-0003-0605-7342","observed_orcids":["https://orcid.org/0000-0003-0605-7342"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hiroto Inaba","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110474857","display_name":"Gary Van Houten Dahl","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gary V.H. Dahl","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065634145","display_name":"Jeffrey E. Rubnitz","orcid":"https://orcid.org/0000-0001-9885-3527","observed_orcids":["https://orcid.org/0000-0001-9885-3527"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeffrey Rubnitz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5077260725","display_name":"Sharyn D. Baker","orcid":"https://orcid.org/0000-0003-3062-3252","observed_orcids":["https://orcid.org/0000-0003-3062-3252"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sharyn D. Baker","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9848999977111816,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9848999977111816,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.009399999864399433,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.002199999988079071,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9860000014305115},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9639999866485596},{"id":"https://openalex.org/keywords/sorafenib","display_name":"sorafenib","score":0.9800000190734863},{"id":"https://openalex.org/keywords/sunitinib","display_name":"sunitinib","score":0.996999979019165},{"id":"https://openalex.org/keywords/imatinib","display_name":"imatinib","score":1.0},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.7250000238418579},{"id":"https://openalex.org/keywords/flt3-itd-mutation","display_name":"FLT3-ITD","score":0.8759999871253967},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.8479999899864197},{"id":"https://openalex.org/keywords/cell-cycle","display_name":"cell cycle","score":0.6480000019073486},{"id":"https://openalex.org/keywords/mapk-signaling","display_name":"MAPK signaling","score":0.8629999756813049},{"id":"https://openalex.org/keywords/akt-signaling","display_name":"Akt signaling","score":0.8690000176429749},{"id":"https://openalex.org/keywords/plasma-protein-binding","display_name":"plasma protein binding","score":0.8240000009536743},{"id":"https://openalex.org/keywords/intracellular-drug-accumulation","display_name":"intracellular drug accumulation","score":0.824999988079071},{"id":"https://openalex.org/keywords/leukemia-cell-lines","display_name":"leukemia cell lines","score":0.6060000061988831}],"concepts":[{"id":"https://openalex.org/C2779490328","wikidata":"https://www.wikidata.org/wiki/Q417542","display_name":"Sunitinib","level":3,"score":0.9297254085540771},{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.9171245098114014},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.6380429863929749},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.5740683078765869},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.5644234418869019},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5562587976455688},{"id":"https://openalex.org/C180361614","wikidata":"https://www.wikidata.org/wiki/Q7202242","display_name":"Platelet-derived growth factor receptor","level":4,"score":0.4663405120372772},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4384024441242218},{"id":"https://openalex.org/C75217442","wikidata":"https://www.wikidata.org/wiki/Q423650","display_name":"Protein kinase B","level":3,"score":0.43498554825782776},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4269292950630188},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.42079809308052063},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.3546779453754425},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3222835063934326},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.23444226384162903},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.19497016072273254},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.18063536286354065},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.12907961010932922},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.11725103855133057},{"id":"https://openalex.org/C2775960820","wikidata":"https://www.wikidata.org/wiki/Q408378","display_name":"Growth factor","level":3,"score":0.10786131024360657},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.06921890377998352},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1535-7163.c.6532041.v1","doi":"https://doi.org/10.1158/1535-7163.c.6532041.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.c.6532041.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.c.6532041.v1","doi":"https://doi.org/10.1158/1535-7163.c.6532041.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.c.6532041.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2146798222","https://openalex.org/W2894865721","https://openalex.org/W2248205070","https://openalex.org/W2536133514","https://openalex.org/W2328657738","https://openalex.org/W2065535177","https://openalex.org/W4292139780","https://openalex.org/W2111639514","https://openalex.org/W7095142036","https://openalex.org/W2592287325"],"abstract_inverted_index":{"Abstract":[0],"We":[1],"compared":[2],"the":[3,7,27,151,225,240,252],"antitumor":[4],"activities":[5],"of":[6,29,47,72,109,150,208,211,227,229,243,254],"multitargeted":[8],"tyrosine":[9,76],"kinase":[10,77,139],"inhibitors":[11,46,71],"imatinib,":[12,61],"sorafenib,":[13,62],"and":[14,41,57,63,67,84,87,93,103,113,120,170,187,213,220],"sunitinib":[15,42,68,114,126,161,186,212],"to":[16,23,54],"determine":[17],"which":[18],"inhibitor":[19],"is":[20],"best":[21],"suited":[22],"be":[24],"used":[25],"for":[26,60],"treatment":[28,253],"acute":[30],"myelogenous":[31],"leukemia":[32],"(AML).":[33],"In":[34,96],"nine":[35,230],"human":[36,163],"AML":[37,196,216,232],"cell":[38,98,121,152,171,197],"lines,":[39],"sorafenib":[40,112,181,190,209,223,244],"were":[43,69],"more":[44,158,183,205],"potent":[45,70,184],"cellular":[48],"proliferation":[49,226],"than":[50,160,185,210],"imatinib":[51,214],"(IC50,":[52,82,91],"0.27":[53],">40,":[55],"0.002-9.1,":[56],"0.007-13":[58],"\u03bcmol/L":[59],"sunitinib,":[64],"respectively).":[65],"Sorafenib":[66,155],"cells":[73],"with":[74,192],"fms-like":[75],"3":[78],"internal":[79],"tandem":[80],"duplication":[81],"2":[83],"7":[85],"nmol/L)":[86],"c-KIT":[88],"N822K":[89],"mutations":[90],"23":[92],"40":[94],"nmol/L).":[95],"four":[97],"lines":[99,153,198],"(MV4-11,":[100],"Kasumi-1,":[101],"KG-1,":[102],"U937)":[104],"that":[105,125,180,188,245],"spanned":[106],"a":[107],"range":[108],"drug":[110],"sensitivities,":[111],"had":[115,142],"similar":[116],"activity":[117,193],"in":[118,131,148,162,201,215,251],"apoptosis":[119,130],"cycle":[122],"assays,":[123],"except":[124],"did":[127],"not":[128],"promote":[129],"U937":[132],"cells.":[133,217],"Both":[134],"drugs":[135],"inhibited":[136,224],"mitogen-activated":[137],"protein":[138],"signaling":[140,147],"but":[141],"no":[143],"effect":[144],"on":[145],"AKT":[146],"most":[149,195],"tested.":[154],"was":[156,182,204],"substantially":[157],"bound":[159],"plasma":[164],"(unbound":[165,174],"fraction,":[166,175],"0.59%":[167],"versus":[168,177],"8.4%)":[169],"culture":[172],"medium":[173],"1.3%":[176],"39%),":[178],"indicating":[179],"unbound":[189],"concentrations":[191],"against":[194],"are":[199],"achievable":[200],"vivo.":[202],"There":[203],"intracellular":[206],"accumulation":[207],"Between":[218],"1":[219],"10":[221],"\u03bcmol/L,":[222],"six":[228],"primary":[231],"blast":[233],"samples":[234],"by":[235],"\u226550%.":[236],"Our":[237],"results":[238],"highlight":[239],"pharmacologic":[241],"features":[242],"may":[246],"provide":[247],"it":[248],"an":[249],"advantage":[250],"AML.":[255],"[Mol":[256],"Cancer":[257],"Ther":[258],"2008;7(5):1110\u201320]":[259]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2023-04-05T00:00:00"}